Cargando…

Virological measures and factors associated with outcomes, and missing outcome data in HIV clinical trials: a methodological study

BACKGROUND: To evaluate the definition of HIV virological outcomes in the literature and factors associated with outcomes and missing outcome data. METHODS: We conducted a methodological review of HIV RCTs using a search (2009–2019) of PubMed, Embase and the Cochrane Central Register of Controlled T...

Descripción completa

Detalles Bibliográficos
Autores principales: Youssef, Mark, Zani, Babalwa, Olaiya, Oluwatobi, Soliman, Michael, Mbuagbaw, Lawrence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547356/
https://www.ncbi.nlm.nih.gov/pubmed/34697107
http://dx.doi.org/10.1136/bmjopen-2020-039462
_version_ 1784590363340570624
author Youssef, Mark
Zani, Babalwa
Olaiya, Oluwatobi
Soliman, Michael
Mbuagbaw, Lawrence
author_facet Youssef, Mark
Zani, Babalwa
Olaiya, Oluwatobi
Soliman, Michael
Mbuagbaw, Lawrence
author_sort Youssef, Mark
collection PubMed
description BACKGROUND: To evaluate the definition of HIV virological outcomes in the literature and factors associated with outcomes and missing outcome data. METHODS: We conducted a methodological review of HIV RCTs using a search (2009–2019) of PubMed, Embase and the Cochrane Central Register of Controlled Trials. Only full-text, peer-reviewed, randomised controlled trials (RCTs) that measured virological outcomes in people living with HIV, and published in English were included. We extracted study details and outcomes. We used logistic regression to identify factors associated with a viral threshold ≤50 copies/mL and linear regression to identify factors associated with missing outcome data. RESULTS: Our search yielded 5847 articles; 180 were included. A virological outcome was the primary outcome in 73.5% of studies. 89 studies (49.4%) used virological success. The remaining used change in viral load (VL) (33 studies, 18.3%); virological failure (59 studies, 32.8%); or virological rebound (9 studies, 5.0%). 96 studies (53.3%) set the threshold at ≤50 copies/mL; and 33.1% used multiple measures. Compared with government and privately funded studies, RCTs with industry funding (adjusted OR 6.39; 95% CI 2.15 to 19.00; p<0.01) were significantly associated with higher odds of using a VL threshold of ≤50 copies/mL. Publication year, intervention type, income level and number of patients were not associated with a threshold of ≤50 copies/mL. Trials with pharmacological interventions had less missing data (β=−11.04; 95% CI −20.02 to −1.87; p=0.02). DISCUSSION: Country source of funding was associated with VL threshold choice and studies with pharmacological interventions had less missing data, which may in part explain heterogeneous virological outcomes across studies. Multiple measures of VL were not associated with missing data. The development of formal guidelines on virological outcome reporting in RCTs is needed.
format Online
Article
Text
id pubmed-8547356
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-85473562021-10-29 Virological measures and factors associated with outcomes, and missing outcome data in HIV clinical trials: a methodological study Youssef, Mark Zani, Babalwa Olaiya, Oluwatobi Soliman, Michael Mbuagbaw, Lawrence BMJ Open Epidemiology BACKGROUND: To evaluate the definition of HIV virological outcomes in the literature and factors associated with outcomes and missing outcome data. METHODS: We conducted a methodological review of HIV RCTs using a search (2009–2019) of PubMed, Embase and the Cochrane Central Register of Controlled Trials. Only full-text, peer-reviewed, randomised controlled trials (RCTs) that measured virological outcomes in people living with HIV, and published in English were included. We extracted study details and outcomes. We used logistic regression to identify factors associated with a viral threshold ≤50 copies/mL and linear regression to identify factors associated with missing outcome data. RESULTS: Our search yielded 5847 articles; 180 were included. A virological outcome was the primary outcome in 73.5% of studies. 89 studies (49.4%) used virological success. The remaining used change in viral load (VL) (33 studies, 18.3%); virological failure (59 studies, 32.8%); or virological rebound (9 studies, 5.0%). 96 studies (53.3%) set the threshold at ≤50 copies/mL; and 33.1% used multiple measures. Compared with government and privately funded studies, RCTs with industry funding (adjusted OR 6.39; 95% CI 2.15 to 19.00; p<0.01) were significantly associated with higher odds of using a VL threshold of ≤50 copies/mL. Publication year, intervention type, income level and number of patients were not associated with a threshold of ≤50 copies/mL. Trials with pharmacological interventions had less missing data (β=−11.04; 95% CI −20.02 to −1.87; p=0.02). DISCUSSION: Country source of funding was associated with VL threshold choice and studies with pharmacological interventions had less missing data, which may in part explain heterogeneous virological outcomes across studies. Multiple measures of VL were not associated with missing data. The development of formal guidelines on virological outcome reporting in RCTs is needed. BMJ Publishing Group 2021-10-22 /pmc/articles/PMC8547356/ /pubmed/34697107 http://dx.doi.org/10.1136/bmjopen-2020-039462 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Epidemiology
Youssef, Mark
Zani, Babalwa
Olaiya, Oluwatobi
Soliman, Michael
Mbuagbaw, Lawrence
Virological measures and factors associated with outcomes, and missing outcome data in HIV clinical trials: a methodological study
title Virological measures and factors associated with outcomes, and missing outcome data in HIV clinical trials: a methodological study
title_full Virological measures and factors associated with outcomes, and missing outcome data in HIV clinical trials: a methodological study
title_fullStr Virological measures and factors associated with outcomes, and missing outcome data in HIV clinical trials: a methodological study
title_full_unstemmed Virological measures and factors associated with outcomes, and missing outcome data in HIV clinical trials: a methodological study
title_short Virological measures and factors associated with outcomes, and missing outcome data in HIV clinical trials: a methodological study
title_sort virological measures and factors associated with outcomes, and missing outcome data in hiv clinical trials: a methodological study
topic Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547356/
https://www.ncbi.nlm.nih.gov/pubmed/34697107
http://dx.doi.org/10.1136/bmjopen-2020-039462
work_keys_str_mv AT youssefmark virologicalmeasuresandfactorsassociatedwithoutcomesandmissingoutcomedatainhivclinicaltrialsamethodologicalstudy
AT zanibabalwa virologicalmeasuresandfactorsassociatedwithoutcomesandmissingoutcomedatainhivclinicaltrialsamethodologicalstudy
AT olaiyaoluwatobi virologicalmeasuresandfactorsassociatedwithoutcomesandmissingoutcomedatainhivclinicaltrialsamethodologicalstudy
AT solimanmichael virologicalmeasuresandfactorsassociatedwithoutcomesandmissingoutcomedatainhivclinicaltrialsamethodologicalstudy
AT mbuagbawlawrence virologicalmeasuresandfactorsassociatedwithoutcomesandmissingoutcomedatainhivclinicaltrialsamethodologicalstudy